<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409135</url>
  </required_header>
  <id_info>
    <org_study_id>AGS-22M6E-11-1</org_study_id>
    <nct_id>NCT01409135</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4</brief_title>
  <official_title>A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS-22M6E or ASG-22CE Given as Monotherapy Followed by Expansion Cohorts in Subjects With Malignant Solid Tumors That Express Nectin-4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agensys, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study examining the safety of AGS-22M6E or ASG-22CE administered as monotherapy therapy in&#xD;
      subjects with malignant solid tumors that express Nectin-4.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AGS-22M6E and ASG-22CE are fully human monoclonal antibody conjugated to a cytotoxic agent&#xD;
      monomethyl auristatin E (MMAE) targeting Nectin-4 (Agensys code name AGS-22). The main&#xD;
      difference between AGS-22M6E and ASG-22CE is the change in cell line for antibody production.&#xD;
      AGS-22M6E and ASG-22CE will be administered at mg/kg doses based on the subjects weight at&#xD;
      baseline and doses will not change unless the subjects weight changes by ≥ 10% from their&#xD;
      baseline weight or the investigational product Dosage Assessment criteria is met.&#xD;
&#xD;
      Subjects will be prescreened for Nectin-4 expression prior to undergoing screening procedures&#xD;
      for the main study. Subjects with tumors positive for Nectin-4 expression may be screened for&#xD;
      eligibility into the main study. The dose escalation period is estimated to take between 12&#xD;
      and 18 months depending on whether 3 or 6 subjects are enrolled in a given dose cohort, and&#xD;
      the availability of consenting subjects.&#xD;
&#xD;
      Subjects will be treated in the dose escalation phase of the study until the maximum&#xD;
      tolerated dose (MTD) and recommended dose for expansion (RDE) has been determined by the data&#xD;
      review team (DRT). After the RDE has been determined, subjects will be enrolled into 1 of 3&#xD;
      expansion cohorts. There will be 3 expansion cohorts, each targeting a specific cancer&#xD;
      (i.e.,Breast, Bladder and Lung plus other solid tumor cancers). The DRT may recommend&#xD;
      stopping the study, adjusting the dose or amending the trial at any time.&#xD;
&#xD;
      The clinical bridging to the ASG-22CE involves treating the subjects with ASG-22CE,&#xD;
      irrespective of cancer type, at the next lowest dose level previously determined to be safe&#xD;
      for AGS-22M6E. After the initial subjects are treated at the bridging dose with ASG-22CE and&#xD;
      have completed the safety assessment, future subjects will only be treated with ASG-22CE&#xD;
      throughout the remainder of the study.&#xD;
&#xD;
      A disease assessment will be performed by the investigator at Week 8 (± 14 days). Subjects&#xD;
      without evidence of disease progression may continue to receive treatment until disease&#xD;
      progression or intolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 28 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Pharmacokinetics: Ceoi or Cmax, Ctrough, Tmax, AUC0-21, t½, CL, Vss</measure>
    <time_frame>Up to 28 days after the last dose of study drug</time_frame>
    <description>Concentration at the end of infusion (Ceoi) or Cmax, trough concentration (Ctrough), Tmax, partial AUC after first dose (AUC0-21), terminal or apparent terminal half-life (t1/2), systemic clearance (CL), volume of distribution at steady state (Vss)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody formation</measure>
    <time_frame>Up to 28 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate</measure>
    <time_frame>Every 8 weeks (± 14 days)</time_frame>
    <description>Incidence of a tumor response is defined as a complete or partial response per Response Criteria for Solid Tumors (RECIST version 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Every 8 weeks (± 14 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Tumors</condition>
  <condition>Medical Oncology</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASG-22CE Expansion Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breast Cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASG-22CE Expansion Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bladder Cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASG-22CE Expansion Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lung plus other solid tumor cancers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGS-22M6E</intervention_name>
    <description>IV Infusion</description>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 1</arm_group_label>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 2</arm_group_label>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 3</arm_group_label>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 4</arm_group_label>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 5</arm_group_label>
    <arm_group_label>AGS-22M6E-11-1 Dose Level 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASG-22CE</intervention_name>
    <description>IV Infusion</description>
    <arm_group_label>ASG-22CE Expansion Cohort 1</arm_group_label>
    <arm_group_label>ASG-22CE Expansion Cohort 2</arm_group_label>
    <arm_group_label>ASG-22CE Expansion Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (For Dose Escalation and Dose Expansion)&#xD;
&#xD;
          -  Subjects must have a tumor positive for Nectin-4 expression (as measured by central&#xD;
             laboratory using primary or metastatic tumor tissue&#xD;
&#xD;
          -  Histologically confirmed malignant solid tumors (excluding sarcoma) that have failed&#xD;
             all FDA approved therapies indicated for the type of metastatic cancer and line of&#xD;
             therapy or for which they were not a candidate to receive treatment&#xD;
&#xD;
          -  Measurable disease according to RECIST criteria (version 1.1) (Eisenhauer, et. al.)&#xD;
             defined as tumor lesions that are accurately measured in at least one dimension&#xD;
             (longest diameter in the plane of measurement is to be recorded) with a minimum size&#xD;
             of:&#xD;
&#xD;
               -  10mm by CT scan (CT scan slice thickness no greater than 5mm&#xD;
&#xD;
               -  10 mm caliper measurement by clinical exam (lesions which cannot be accurately&#xD;
                  measured with calipers should be recorded as nonmeasurable&#xD;
&#xD;
               -  20 mm by chest X-ray&#xD;
&#xD;
               -  ≥ 15 mm in short axis for lymph nodes when assessed by CT scan (CT scan slice&#xD;
                  thickness recommended to be no greater than 5 mm)&#xD;
&#xD;
        Note: bone lesions, ascites, and pleural effusions are not considered measurable lesions&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Negative pregnancy test (women of childbearing potential)&#xD;
&#xD;
          -  Hematologic function, as follows:&#xD;
&#xD;
               -  a. Absolute neutrophil count (ANC) ≥ 1.0 x109 /L&#xD;
&#xD;
               -  b. Platelet count ≥ 100 x 109/L&#xD;
&#xD;
               -  c. Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  Renal function, as follows: serum creatinine ≤ 2.0 mg/dL, or measured 24 hour&#xD;
             creatinine clearance of ≥ 45 mL/min&#xD;
&#xD;
          -  Total bilirubin ≤1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum albumin &gt; 2.5 g/dL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) ≤ 1.5 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) ≤ 1.5 x ULN&#xD;
&#xD;
          -  Gamma GT ≤1.5 ULN&#xD;
&#xD;
          -  International normalized ratio (INR) &lt; 1.5 (or ≤ 3 if on warfarin or other medications&#xD;
             for therapeutic anticoagulation)&#xD;
&#xD;
          -  Women and men of childbearing potential must be advised and agree to practice&#xD;
             effective methods of contraception during the course of the study&#xD;
&#xD;
        Inclusion Criteria for Dose Expansion Only:&#xD;
&#xD;
        In addition to the inclusion criteria listed above, the following criteria will also be&#xD;
        required for each expansion cohort:&#xD;
&#xD;
        Expansion Cohort 1: Breast Cancer&#xD;
&#xD;
          -  Subjects with Histologically or cytologically diagnosed metastatic breast cancer&#xD;
&#xD;
        Expansion Cohort 2: Bladder Cancer&#xD;
&#xD;
          -  Histologically or cytologically confirmed bladder cancer with visceral metastases&#xD;
&#xD;
        Expansion Cohort 3: Lung plus other solid tumor cancer&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic non-small cell lung cancer&#xD;
             (NSCLC) or any other solid tumor cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preexisting neuropathy Grade ≥ 3 or motor neuropathy Grade ≥ 2&#xD;
&#xD;
          -  Uncontrolled brain or epidural spinal metastases&#xD;
&#xD;
          -  Use of any investigational drug within 14 days or 5 half-lives prior to first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Any anticancer therapy including: small molecules, immunotherapy, chemotherapy,&#xD;
             monoclonal antibody therapy, radiotherapy or any other agents to treat cancer within&#xD;
             28 days prior to first dose of study drug&#xD;
&#xD;
          -  Active angina or Class III or IV Congestive Heart Failure (New York Heart Association&#xD;
             CHF Functional Classification System) or clinically significant cardiac disease within&#xD;
             12 months of the first dose of study drug, including myocardial infarction, unstable&#xD;
             angina, grade 2 or greater peripheral vascular disease, congestive heart failure,&#xD;
             uncontrolled hypertension, or arrhythmias not controlled by medication&#xD;
&#xD;
          -  Known HIV or AIDS&#xD;
&#xD;
          -  Decompensated liver disease as evidenced by clinically significant ascites refractory&#xD;
             to diuretic therapy, hepatic encephalopathy, or coagulopathy&#xD;
&#xD;
          -  History of thromboembolic events and bleeding disorders ≤ 3 months (e.g.,deep vein&#xD;
             thrombosis ( DVT) or pulmonary embolism ( PE)) prior to first dose of study drug&#xD;
&#xD;
          -  Major surgery within 28 days prior to first dose of study drug&#xD;
&#xD;
          -  Active infection requiring treatment ≤7 days prior to first dose of study drug&#xD;
&#xD;
          -  Anti-androgen therapy initiated within 28 days of enrollment (for prostate cancer&#xD;
             patients only)&#xD;
&#xD;
          -  Positive Hepatitis B surface antigen test&#xD;
&#xD;
          -  Positive Hepatitis C antibody test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Agensys, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver-Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nectin 4 protein, humans</keyword>
  <keyword>Cancer</keyword>
  <keyword>Pharmacokinetics of AGS-22M6E</keyword>
  <keyword>Pharmacokinetics of ASG-22CE</keyword>
  <keyword>Safety</keyword>
  <keyword>Clinical Trial, Phase 1</keyword>
  <keyword>ASG-22ME</keyword>
  <keyword>AGS-22M6E</keyword>
  <keyword>ASG-22CE</keyword>
  <keyword>ASG-22C3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

